EP0831931A1 - Modele in vivo et in vitro de photovieillissement cutane - Google Patents

Modele in vivo et in vitro de photovieillissement cutane

Info

Publication number
EP0831931A1
EP0831931A1 EP96920342A EP96920342A EP0831931A1 EP 0831931 A1 EP0831931 A1 EP 0831931A1 EP 96920342 A EP96920342 A EP 96920342A EP 96920342 A EP96920342 A EP 96920342A EP 0831931 A1 EP0831931 A1 EP 0831931A1
Authority
EP
European Patent Office
Prior art keywords
mice
uva
uvb
transgenic mouse
skin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP96920342A
Other languages
German (de)
English (en)
Other versions
EP0831931A4 (fr
Inventor
Eric Bernstein
Jouni Uitto
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Charles River Breeding Laboratories Inc
Original Assignee
Thomas Jefferson University
Abtech Industries Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/449,826 external-priority patent/US5648061A/en
Application filed by Thomas Jefferson University, Abtech Industries Inc filed Critical Thomas Jefferson University
Publication of EP0831931A1 publication Critical patent/EP0831931A1/fr
Publication of EP0831931A4 publication Critical patent/EP0831931A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0393—Animal model comprising a reporter system for screening tests

Definitions

  • Cutaneous aging results from both intrinsic chronological aging and extrinsic sun-exposure. Montagna et al., J. Am. Acad. Dermatol . 1989, 21:907-918; Kligman, L.H., Aging and the Skin. Raven Press, New York, 1989, pp. 331-346; Taylor et al., J. Am. Acad. Dermatol . 1990, 221:1-15. The majority of changes associated with an aged appearance result from chronic sun- damage. Warren et al., J. Am. Acad. Dermatol . 1991, 25:751- 760; Frances, C. and Robert, L., Int. J. Dermatol . 1984, 23:166-179.
  • Elevated elastin RNA levels in sun-damaged skin result from enhanced elastin promoter activity, as shown by transient transfections of fibroblasts with a DNA construct composed of the human elastin promoter linked to the chloramphenicol acetyltransferase (CAT) reporter gene. Bernstein et al., J. Invest . Dermatol . 1994, 103:182-186.
  • CAT chloramphenicol acetyltransferase
  • a transgenic mouse line which expresses the human elastin promoter/CAT construct has now been developed to further study the role of elastin promoter activation in cutaneous photoaging.
  • These mice express human elastin promoter activity in a tissue-specific and developmentally regulated manner. Promoter activity can be studied in this model as a function of small increases in ultraviolet radiation, demonstrating the sensitivity of the assay. In addition quantitative data can be obtained after only a single exposure to ultraviolet radiation.
  • This transgenic mouse and fibroblasts derived from this mouse are useful as In vivo and in vitro models to study cutaneous photoaging and in the identification of agents which may protect against photodamage.
  • An object of the present invention is to provide a transgenic mouse capable of expressing human elastin promoter.
  • Another object of the present invention is to provide mouse fibroblast cultures derived from a transgenic mouse capable of expressing human elastin promoter.
  • a transgenic mouse model has been developed which permits the investigation of human elastin promoter activity in response to ultraviolet irradiation both in vivo by direct irradiation of mouse skin, and in vitro by irradiation of dermal fibroblasts grown from skin explants.
  • Previous studies investigating the effect of ultraviolet radiation on photoaging in animal models have measured elastic fiber damage, solar elastosis, skin wrinkling, and skin sagging.
  • the similarity between the mouse and human action spectra for development of edema and erythema in response to ultraviolet radiation suggests that mouse models may accurately mimic human responses to ultraviolet radiation. For example, wrinkling of mouse skin mimics human wrinkling which occurs in chronically photodamaged skin.
  • mice do not develop erythema in a manner similar to humans and the elastic fiber alterations in mice in response to ultraviolet radiation are qualitatively different from those occurring in chronically sun-damaged human skin.
  • the numerous dermal cysts present in hairless mice proliferate in response to ultraviolet radiation, a response which has no clinical correlate in human skin. Skin sagging, a response in certain mice to high dose UVA, does not appear to have a histopathologic correlate in mice and may not have a clinical correlation to a human response.
  • mouse skin is relatively thin in comparison to human skin, thus, permitting better penetration of ultraviolet radiation. This may, in part, account for the accentuated response of mouse skin to ultraviolet radiation.
  • the decreased thickness of mouse skin may also exaggerate the potential effects of UVB as compared to UVA, relative to humans. UVB penetrates only the most superficial dermis in humans, whereas in mice, the relative proportion of the dermis exposed to UVB is much greater. Utilizing the human elastin promoter in the transgenic mouse model of the present, is believed to more accurately reflect the human response to ultraviolet radiation. The approximate time of maximal promoter activation and the duration of promoter elevation after a single exposure of UVA or UVB radiation was determined.
  • mice were treated with a single dose of 245.7 mJ/cm 2 of UVB or 38.2 J/cm 2 of UVA.
  • Elastin promoter activity was maximal 24 hours after UVB exposure with a 4.6-fold increase over controls.
  • CAT activity remained elevated 72 hours after irradiation at nearly 2 times control levels. By 96 hours, the activity fell to below one-third that of controls.
  • UVA irradiation CAT activity was maximal 12-24 hours after light exposure, demonstrating a more modest increase of less than twice that of controls. This increase persisted until 48 hours after UVA exposure. By 72 hours after UVA exposure, CAT activity fell to one-third that of controls.
  • mice were harvested 1, 2, 3 and 6 hours following UVB exposure. A 20% increase in CAT activity was measured 1 hour following exposure while a 70% elevation was measured 2 hours after exposure.
  • mice The dose-response relationship for elastin promoter activity in UVB-treated mice was observed after only a single dose of UVB. Other in vivo models of photoaging require numerous treatments over a much longer period of time to demonstrate a measurable effect.
  • Experimentally produced elastosis in mice was first produced by Sams et al. using very large amounts of ultraviolet radiation. J. Invest . Dermatol . 1964, 43:467-471. In these studies, one group of mice received 1,040 human minimal erythema doses ( EDs) over 3 months from a bank of fluorescent tubes, while another group received 13,000 MEDs given over 52 weeks in 260 treatments.
  • EDs human minimal erythema doses
  • Elastosis was demonstrated by histochemical staining for elastin and, in irradiated mice, demonstrated an increased elastin staining. Since this initial report, a number of researchers have used murine models of cutaneous photoaging evaluating the production of dermal elastosis. Sams et al., J. Invest . Dermatol . 1964, 43:467-471; Nakamura, K. and Johnson, W.C., J. Invest . Dermatol . 1968, 51:253-258; Berger et al., Arch. Dermatol . Res. 1980, 269:39-49; Kligman, L.H., Arch. Dermatol . Res .
  • the elevation of the elastin promoter in response to UVB and UVA was also determined to be dose dependent. Increasing doses of ultraviolet radiation were administered and skin harvested 24 hours after light exposure. In response to UVB irradiation at 30.7, 122.8 and 491.4 mJ/cm 2 , CAT activity increased to 1.7-, 4.1- and 8.5-fold greater than controls, respectively. In response to UVA irradiation, a more modest increase in CAT activity was seen. Doses of 9.5 and 38.2 J/cm 2 resulted in increases of 1.6- and 1.7-fold over controls, respectively.
  • the transgenic mouse model of the present invention yields quantitative data.
  • Kligman and Sayre Photochem. Photobiol . 1991, 53:237-242
  • the parameters used to assess degree of elastosis in the prior art were evaluated subjectively.
  • the effect of ultraviolet radiation on CAT activity in vitro was also determined.
  • Early passage fibroblasts derived from skin explants of the transgenic mice were irradiated and harvested for determination of CAT activity 24 hours later.
  • Doses of UVB ranged from 0.7 to 10.9 mJ/cm 2 , with the highest doses resulting in over a 30-fold increase in CAT activity.
  • Promoter activity as measured by CAT assay, peaked at a dose of 5.5 mJ/cm 2 , which corresponded with a treatment time of 40 seconds.
  • CAT activity remained elevated at about 30-fold with increasing UVB doses, eventually resulting in a decrease in CAT activity which corresponds with cell death.
  • UVA doses of up to 2.2 J/cm 2 which corresponds with a light treatment time of over 18 minutes, did not increase CAT activity in vitro. Longer treatment times resulted in cell death.
  • PUVA-treated cell cultures demonstrated 2.6-, 13.2- and 2.0- fold increases in CAT activity in response to 1 J/cm 2 of UVA with 8-MOP doses of 0.3, 1.0, and 3.0 ⁇ g/ml of 8-MOP, respectively.
  • 8-MOP doses 3 ⁇ g/ml
  • the induction of elastin promoter activity decreased signif cantly at this dose presumably due to decreased cell viability.
  • Protein assays demonstrated a dose- dependent reduction in total protein harvested indicative of cell death at the highest 8-MOP doses.
  • mice treated with 8-MOP or UVA alone did not exhibit a significant change in CAT activity, as compared to untreated controls.
  • PUVA- treated mice demonstrated a 3.1-fold increase in CAT activity demonstrating in vivo activation of the elastin promoter in response to PUVA as well.
  • the transgenic mouse model of the present invention provides a rapid, quantitative means of measuring human elastin promoter activity in response to single doses of ultraviolet radiation. Enhanced CAT activity was demonstrated in response to both UVA and UVB. Further, the ability to study the effects of ultraviolet radiation both in vivo and in vitro enables further investigation of the mechanisms responsible for elastin promoter activation by ultraviolet radiation.
  • This model also provides a tool for the rapid evaluation of sunscreens and other compounds thought to alter the effects of solar radiation. In addition, this model can be used to study the effects of treatments such as psoralen on a specific gene as in the studies performed with PUVA treatment.
  • a test compound is applied to the skin of a transgenic mouse capable of expressing human elastin promoter.
  • the transgenic mouse is then exposed to ultraviolet radiation, either UVB or UVA and human elastin promoter activity in the mouse is determined.
  • the transgenic mouse is exposed to 8-MOP followed by UVA.
  • the human elastin promoter activity is then compared to that in transgenic mice also exposed to an equivalent dose of ultraviolet radiation which were not treated with the test compound to determine whether or not the test compound provided protection against the ultraviolet radiation.
  • fibroblast cells derived from a transgenic mouse capable of expressing human elastin promoter are treated with a test compound.
  • the treated fibroblast cells are then exposed to UVB radiation or 8-MOP followed by UVA radiation and human elastin promoter activity in the fibroblast cells is determined.
  • This activity is compared to fibroblast cells from the transgenic mice exposed to the same dose of UVB radiation or 8-MOP followed by UVA radiation but which were not treated with the test compound to determine if the test compound provided protection against the exposure.
  • Example 1 Transgenic mice expressing the human elastin promoter
  • mice expressing the 5.2- kb human elastin promoter linked to a CAT reporter gene were used. Hsu-Wong et al., J. Biol . Chem. 1994, 269:18072-18075. These mice express the human elastin promoter in a tissue- specific and developmentally regulated manner. Mice four or five days old were used since at this age, visible hair growth is not yet present.
  • Fibroblast cultures were established from the skin of transgenic mice by explanting tissue specimens onto the tissue culture plastic dishes and allowing cells to migrate to the surrounding area.
  • the primary cultures were maintained in Dulbecco's modified Eagle's (DME) medium supplemented with 10% fetal calf serum, 1 mM L-glutamine and antibiotics at 37°C.
  • DME Dulbecco's modified Eagle's
  • the primary cell cultures were passaged by trypsinization and the subcultures in passages 2 or 3 were utilized for radiation experiments. After exposure to ultraviolet radiation, the cells were incubated in DME medium supplemented with 10% fetal calf serum for 24 hours, then harvested for determination of CAT activity as described in Example 3.
  • CAT activity was determined.
  • the specimens were homogenized in 0.25 Tris-HCl, pH 7.5, using a tissue homogenizer (Brinkmann Instruments, Inc. Westbury, NY). The homogenates were centrifuged at 10,000 X g for 15 minutes at 4°C and the protein concentration in the supernatant determined by a commercial protein assay kit (Bio- Rad Laboratories, Richmond, CA).
  • UVB radiation For administration of UVB radiation, a closely spaced array of seven Westinghouse FS-40 sunlamps was used which delivered uniform irradiation at a distance of 35 cm. Irradiating with UVA was performed using seven Sylvania FR40T12 PUVA lamps in the above mentioned array, filtered through window glass of 2 mm thickness to remove wavelengths below 320 nm. The energy output at 35 cm was measured with a Solar Light model 3D UVA and UVB detector (Solar Light Company, Philadelphia, PA). The output of FX-40 sunlamps was 23.4 units/hour of UVB at 38 cm, where each unit is equivalent to 21 mJ/cm 2 of erythema effective energy. The output for FR40T12 PUVA lamps filtered through window glass was 2.02 mW/cm 2 , with no detectable UVB radiation.
  • mice were placed under the center of the light array and restrained with adhesive tape, exposing their dorsal surfaces to the ultraviolet radiation at a distance of 35 cm from the fluorescent tubes. Untreated control mice were restrained in a similar manner. To determine the time of maximal promoter activation and the duration of elevated promoter activity following UVA and UVB irradiation, time course experiments were carried out. Doses were selected in accordance with amounts showing moderate promoter activation. Mice were irradiated for one-half hour with UVB (dose of 245.7 mJ/cm 2 ) or with UVA for 5.2 hours (dose of 38.2 J/cm 2 ). Irradiated skin was then harvested over the next 72 to 96 hours for determination of CAT activity.
  • UVB dose of 245.7 mJ/cm 2
  • UVA for 5.2 hours
  • mice were sacrificed at the first time point (12 hours after irradiation). To determine the earliest response of CAT activity to UVB irradiation, mice were harvested 1, 2, 3 and 6 hours after UVB exposure. Unirradiated mice were harvested 24, 48, 72 and 96 hours after control mice to determine the fall in endogenous CAT activity over time.
  • mice were used for each dose or time point in each experiment.
  • Fibroblast cultures as described above were exposed for 5, 10, 20, 40 and 80 seconds of UVB corresponding to doses of 0.7, 1.4, 2.7, 5.5 and 10.9 mJ/cm 2 , respectively.
  • Cultures were exposed to UVA for 2.3, 4.6, 9.2 and 18.4 minutes corresponding to doses of 0.3, 0.6, 1.1 and 2.2 J/cm 2 .
  • tissue culture medium was removed from cells and replaced with a thin layer of phosphate buffered saline (PBS) sufficient to cover the cells. Control unirradiated cells were also placed in PBS. Medium was replaced in all dishes immediately after the last light dose was administered. Only fibroblasts from mice in the same litters were used for any given experiment and utilized in the first few passages. Two dishes of cells were used for each time point.
  • PBS phosphate buffered saline
  • Control cells received no UVA or 8-MOP.
  • UVA controls received 1 J/cm 2 of UVA without prior incubation with 8-MOP.
  • 8-MOP controls received the highest dose of 8-MOP (3 ⁇ g/ml) but no UVA.
  • PUVA-treated cells were preincubated with either 0.3, 1.0 or 3.0 ⁇ g/ml of 8-MOP in phosphate buffered saline (PBS) and then exposed to 1 J/cm 2 of UVA.
  • 8-MOP was administered by diluting 8-MOP in PBS to the desired concentration. Before application to cultures, tissue culture medium was removed and the cells were rinsed twice with PBS.
  • mice were placed under the center of the light array and restrained with adhesive tape, exposing their dorsal surfaces to UVA at a distance of 38 cm from the fluorescent tubes. Unirradiated control mice were restrained in a similar manner. For each experiment, only mice from the same litter were used. 8-MOP-treated mice received 25 ⁇ l of an ethanolic solution containing 2 mg/ml of 8-MOP, applied twice to their backs 15 and 7.5 minutes before UVA (10 J/cm 2 ) exposure. 8-MOP control mice received identical topical applications of 8-MOP. PUVA-treated mice received both 8-MOP and UVA. Following phototreatment, the backs of the mice were rinsed twice with 70% isopropyl alcohol pads to remove excess 8-MOP. Mice were sacrificed and skin harvested for determination of CAT activity 24 hours after phototreatment.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Environmental Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Diabetes (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention décrit une souris transgénique capable d'exprimer le promoteur de l'élastine humaine, ainsi que des cultures de fibroblastes de souris tirées de ladite souris transgénique. Elle décrit également des procédés permettant d'identifier des composés capables d'inhiber les lésions cutanées provoquées par les rayonnements solaires à l'aide de ladite souris ou des cultures de fibroblastes tirées de souris transgéniques.
EP96920342A 1995-05-24 1996-05-21 Modele in vivo et in vitro de photovieillissement cutane Withdrawn EP0831931A4 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US449826 1995-05-24
US08/449,826 US5648061A (en) 1995-05-24 1995-05-24 In vivo and in vitro model of cutaneous photoaging
US28095P 1995-06-16 1995-06-16
US280 1995-06-16
PCT/US1996/007337 WO1996037237A1 (fr) 1995-05-24 1996-05-21 Modele in vivo et in vitro de photovieillissement cutane

Publications (2)

Publication Number Publication Date
EP0831931A1 true EP0831931A1 (fr) 1998-04-01
EP0831931A4 EP0831931A4 (fr) 2001-09-26

Family

ID=26667437

Family Applications (1)

Application Number Title Priority Date Filing Date
EP96920342A Withdrawn EP0831931A4 (fr) 1995-05-24 1996-05-21 Modele in vivo et in vitro de photovieillissement cutane

Country Status (4)

Country Link
EP (1) EP0831931A4 (fr)
JP (1) JPH11507807A (fr)
CA (1) CA2219976A1 (fr)
WO (1) WO1996037237A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1875927B1 (fr) * 1997-12-17 2011-10-26 The General Hospital Corporation Procédé d'évaluation de l'effet d'un composé sur la peau
US6689936B1 (en) 1997-12-17 2004-02-10 The General Hospital Corp. Method for evaluating a compound for its effect on skin
JP4125486B2 (ja) * 1997-12-17 2008-07-30 株式会社資生堂 化合物を皮膚に対するその効果について評価する方法
US6753146B1 (en) * 1999-02-23 2004-06-22 Eric F. Bernstein System and method for evaluating agents which prevent oxidative damage
CA2362904A1 (fr) * 1999-02-23 2000-08-31 Eric F. Bernstein Systeme et procede d'evaluation d'agents de prevention des destructions oxydatives
AU761728B2 (en) * 1999-02-24 2003-06-05 Charles River Laboratories, Inc. An (in vivo) and (in vitro) model for cutaneous photoaging and oxidative damage
US7163679B1 (en) 1999-05-06 2007-01-16 The General Hospital Corporation Versican and epithelial-mesenchymal interaction

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BERNSTEIN ET AL: 'Enhanced Elastin and Fibrillin Gene Expression in Chronically Photodamaged Skin' JOURNAL OF INVESTIGATIVE DERMATOLOGY vol. 103, no. 2, August 1994, pages 182 - 186 *
BERNSTEIN, ERIC F. ET AL: "8-Methoxypsoralen and ultraviolet A radiation activate the human elastin promoter in transgenic mice: in vivo and in vitro evidence for gene induction" PHOTOCHEM. PHOTOBIOL. (1996), 64(2), 369-374 , XP001015508 *
DATABASE CHEMABS [Online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; BERNSTEIN, ERIC F. ET AL: "Ultraviolet radiation activates the human elastin promoter in transgenic mice: a novel in vivo and in vitro model of cutaneous photoaging" retrieved from STN Database accession no. 123:192455 XP001015512 & J. INVEST. DERMATOL. (1995), 105(2), 269-73 , *
See also references of WO9637237A1 *

Also Published As

Publication number Publication date
CA2219976A1 (fr) 1996-11-28
EP0831931A4 (fr) 2001-09-26
WO1996037237A1 (fr) 1996-11-28
JPH11507807A (ja) 1999-07-13

Similar Documents

Publication Publication Date Title
Bernerd et al. UVA exposure of human skin reconstructed in vitro induces apoptosis of dermal fibroblasts: subsequent connective tissue repair and implications in photoaging
US5648061A (en) In vivo and in vitro model of cutaneous photoaging
Bernstein et al. Ultraviolet radiation activates the human elastin promoter in transgenic mice: a novel in vivo and in vitro model of cutaneous photoaging
US20050208000A1 (en) Compositions and methods for prevention of photoaging
Kawase et al. Exacerbated and prolonged allergic and non-allergic inflammatory cutaneous reaction in mice with targeted interleukin-18 expression in the skin
EP0831931A1 (fr) Modele in vivo et in vitro de photovieillissement cutane
US6018098A (en) In vivo and in vitro model of cutaneous photoaging
AU5612000A (en) Use of nitroxides in wound healing and in the prevention of photodamage
Bernstein et al. Evaluation of sunscreens with various sun protection factors in a new transgenic mouse model of cutaneous photoaging that measures elastin promoter activation
CN108653736A (zh) M2型丙酮酸激酶作为药物靶点在制备防治银屑病的药物中的应用
Zhang Animal Models of Skin Disorders
Petersen et al. Regulation and inhibition of collagenase expression by long‐wavelength ultraviolet radiation in cultured human skin fibroblasts
Keough et al. Elevated epidermal ornithine decarboxylase activity suppresses contact hypersensitivity
Yamazaki et al. XPA gene-deficient, SCF-transgenic mice with epidermal melanin are resistant to UV-induced carcinogenesis
US20060029555A1 (en) Compositions and methods for prevention of photoaging
Schwartz et al. Changes in contractile properties of skeletal muscle during developmentally programmed atrophy and death
Miyauchi-Hashimoto et al. Ultraviolet radiation-induced suppression of natural killer cell activity is enhanced in xeroderma pigmentosum group A (XPA) model mice
US6753146B1 (en) System and method for evaluating agents which prevent oxidative damage
AU761728B2 (en) An (in vivo) and (in vitro) model for cutaneous photoaging and oxidative damage
AU760969B2 (en) System and method for evaluating agents which prevent oxidative damage
EP0906078A1 (fr) Utilisation de tempol dans la prevention du photovieillissement
KR101403570B1 (ko) 알레르겐 피부 감작을 통한 아토피피부염 모델 ＳＫＨ-1 Ｈｒ 마우스 및 이의 제조방법
GANGE et al. Topical spermine and putrescine stimulated DNA synthesis in the hairless mouse epidermis
Pastila et al. In vivo UVA irradiation of mouse is more efficient in promoting pulmonary melanoma metastasis than in vitro
CA2253187C (fr) Utilisation de tempol dans la prevention du photovieillissement

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19971205

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: BERNSTEIN, ERIC

A4 Supplementary search report drawn up and despatched

Effective date: 20010814

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: CHARLES RIVER LABORATORIES

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: CHARLES RIVER LABORATORIES

17Q First examination report despatched

Effective date: 20030923

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20041214